{"disease":{"id":"amyloidosis-familial","name":"amyloidosis familial"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT03237494","title":"TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects","phase":"","overall_status":"COMPLETED","enrollment_count":5028,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false},{"nct_id":"NCT05489549","title":"Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT03431896","title":"Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis","phase":"","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"The Cleveland Clinic","has_results":false},{"nct_id":"NCT03862807","title":"Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT07213297","title":"Comprehensive Program for Hereditary Transthyretin Amyloidosis","phase":"","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Hospital de Alta Complejidad en Red","has_results":false},{"nct_id":"NCT01604122","title":"Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers","phase":"","overall_status":"COMPLETED","enrollment_count":1,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02713880","title":"Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP)","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false},{"nct_id":"NCT02939820","title":"Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}